Gram (GRAM) token experienced a sharp 11.08% drop within one hour on October 23, falling from $1.30 to $1.15 and breaking a months-long price range. This decline marks the first time GRAM has fallen below $1.30 since early August. On the same day, liquidations totaled $5.83 million in long positions and $240,300 in short positions across exchanges, indicating significant market activity. Previously, GRAM had peaked at $1.74 in late September before retreating to the $1.30-$1.35 range that had held since August.
Gram token's sharp 11.08% drop in one hour on October 23 is notable market context. For readers following cryptocurrency, here is Pluang's market snapshot as of Oct 24, 2026 20:01 WIB: out of 50 major cryptocurrencies priced on Pluang, 43 fell and only 5 rose today. Among movers, COTI declined 7.12% to Rp196 with 84% sell order activity, ATOM dropped 7.05% to Rp30,122 with 54% sell orders, and SNX fell 5.18% to Rp3,660 despite 100% buy order activity. Typical hold times range from 61 to 122 days across these assets.
The Royal Canadian Legion has launched its 2026 National Poppy Campaign introducing a new contactless donation method using smartphones, supported by BMO and Toucan Giving technology. This innovation allows volunteers to collect donations via debit, ...
XBiotech Inc. announced the election of Jan-Paul Simard as Co-Chief Executive Officer alongside current CEO Dr. Sushma Shivaswamy, effective October 23, 2026. This leadership change aims to leverage their complementary skills and scientific expertise...
XBiotech Inc. announced the appointment of Sushma Shivaswamy and Jan-Paul Simard as co-chief executive officers, effective October 23, 2026. Shivaswamy, with 17 years at the company, has led scientific operations and was interim CEO since December 20...
Genmab and Incyte announced a Phase 1/2 clinical trial to test a combination of petosemtamab, INCB161734, and standard chemotherapy as a first-line treatment for metastatic colorectal cancer with the KRAS G12D mutation. This mutation is common and li...
Nanobiotix announced positive Phase 1 trial results for JNJ-1900 (NBTXR3), used with radiotherapy and immune checkpoint inhibitors, in 24 heavily pretreated advanced melanoma patients resistant to anti-PD-1 therapies. The treatment showed a 41.7% obj...
